Comparison of Dose Escalation and Co-Therapy Intensification Between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab

被引：0
|
作者：
Thorne, J. Carter [1 ]
Boire, Gilles [2 ]
Chow, Andrew [3 ]
Garces, Kirsten [4 ]
Liu, Fang [5 ]
Poulin-Costello, Melanie [4 ]
Walker, Valery [5 ]
Haraoui, Boulos [6 ]
机构：
[1] Southlake Reg Hlth Ctr, Newmarket, ON, Canada
[2] Univ Sherbrooke, Dept Med, Div Rheumatol, Sherbrooke, PQ J1K 2R1, Canada
[3] Credit Valley Rheumatol, Mississauga, ON, Canada
[4] Amgen Canada Inc, Mississauga, ON, Canada
[5] Optum, Burlington, ON, Canada
[6] Inst Rhumatol Montreal, Montreal, PQ, Canada
来源：
ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
548
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis
    Tang, Boxiong
    Rahman, Mirza
    Waters, Heidi C.
    Callegari, Peter
    CLINICAL THERAPEUTICS, 2008, 30 (07) : 1375 - 1384
  • [42] Budget Impact of Etanercept Versus Adalimumab for Treatment of Rheumatoid Arthritis in Biologic-Naive Patients in the United Kingdom
    Onishchenko, Kateryna
    Tarallo, Miriam
    Curiale, Cinzia
    Alexopoulos, Stamatia Theodora
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [43] Therapy of patients with rheumatoid arthritis: Outcome of infliximab failures switched to etanercept
    Buch, Maya H.
    Bingham, Sarah J.
    Bejarano, Victoria
    Bryer, Domini
    White, Jo
    Emery, Paul
    Reece, Richard
    Quinn, Mark
    ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2007, 57 (03): : 448 - 453
  • [44] Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis
    Rosalía Martínez-Pérez
    Sergio Rodríguez-Montero
    Alejandro Muñoz
    Julia Uceda
    Mario León
    Francisco Gallo
    Maria Luisa Velloso
    José Luis Marenco
    Journal of Translational Medicine, 10 (Suppl 3)
  • [45] Real World Evaluation of Patients with Rheumatoid Arthritis Initiating Tofacitinib Vs. Adalimumab and Etanercept
    Chastek, Benjamin
    Harnett, James
    Curtis, Jeffrey R.
    Gerber, Robert
    Gruben, David
    Song, Rui
    Koenig, Andrew
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [46] Cost-efficacy comparison of adalimumab and etanercept in the treatment of rheumatoid arthritis.
    Singh, A
    Wanke, LA
    Malone, DC
    Ortmeier, BG
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S461 - S461
  • [47] The impact of prior biologic therapy on adalimumab response in patients with rheumatoid arthritis
    Feuchtenberger, M.
    Kleinert, S.
    Scharbatke, E. -C.
    Gnann, H.
    Behrens, F.
    Wittig, B. M.
    Greger, G.
    Tony, H. -P.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (03) : 321 - 329
  • [48] Differential Impact of Biologic Therapy on Heart Function Biomarkers in Rheumatoid Arthritis Patients: Observational Study on Etanercept, Adalimumab, and Tocilizumab
    Dubiel-Braszczok, Beata
    Nowak, Karolina
    Owczarek, Aleksander
    Engelmann, Malgorzata
    Gumkowska-Sroka, Olga
    Kotyla, Przemyslaw J.
    CURRENT PHARMACEUTICAL DESIGN, 2022, 28 (24) : 2029 - 2037
  • [49] Adalimumab dose escalation improves clinical responses in patients with rheumatoid arthritis (RA)
    Karpouzas, George A.
    Moran, Rosalinda
    Khanna, Dinesh
    Louie, James
    Paulus, Harold
    Furst, Daniel
    Cooray, Dilrukshie
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S537 - S537
  • [50] Infliximab dose escalation in patients with rheumatoid arthritis in the START study: Influence of Infliximab pharmacokinetics and immunogenicity
    Rahman, M. U.
    Strusberg, I.
    Geusens, P.
    Wagner, C.
    Han, J.
    Westhovens, R.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2007, 66 : 86 - 86
12345